SCA
ARGS

SAC Capital Advisors’s Argos Therapeutics, Inc. ARGS Stock Holding History

SAC Capital Advisors’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,842
Closed -$368K – 1664
2014
Q1 		$368K Buy
+1,842
New +$368K ﹤0.01% 1316

Other funds holding ARGS

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Caisse de Depot et Placement du Quebec (CDPQ)
Caisse de Depot et Placement du Quebec (CDPQ) Montreal, Quebec, Canada $62.4B AUM 23.7% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PSI
Pinnacle Summer Investments Fairfax, Virginia $678M AUM 9.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SAC Capital Advisors's ARGS Position: Q2 2014 in Review

SAC Capital Advisors sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2014, closing a stake of 1,842 shares — an estimated $368K sold.

SAC Capital Advisors first reported a position in ARGS in Q1 2014 and held it in 1 quarter. The position peaked at $368K in Q1 2014. 30 funds tracked by Wall St. Rank hold ARGS as of Q2 2014.

  • SAC Capital Advisors reported no remaining Argos Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 1,842 Argos Therapeutics, Inc. shares in Q2 2014, an estimated $368K.
  • SAC Capital Advisors first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 1 quarter.
  • SAC Capital Advisors's Argos Therapeutics, Inc. position peaked at $368K in Q1 2014.
  • 30 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.